Abstract. Using two types of anti-phosphopeptide antibodies which specifically recognize vimentin phosphorylated by protein kinase C (PKC) at two distinct PKC sites, we found that PKC acted as a mitotic vimentin kinase. Temporal change of vimentin phosphorylation by PKC differed from changes by cdc2 kinase. The mitosis-specific vimentin phosphorylation by PKC was dramatically enhanced by treatment with a PKC activator, 12-O-tetradecanoylphorbol-13-acetate (TPA), while no phosphorylation of vimentin by PKC was observed in interphase cells treated with TPA. By contrast, the disruption of subcellular compartmentalization of interphase cells led to vimentin phosphorylation by PKC. Cytoplasmic and nuclear membranes are fragmented and dispersed in the cytoplasm and some bind to vimentin during mitosis. Thus, targeting of activated PKC, coupled with the reorganization of intracellular membranes which contain phospholipids essential for activation, leads to the mitosis-specific phosphorylation of vimentin. We propose that during mitosis, PKC may phosphorylate an additional subset of proteins not phosphorylated in interphase.
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We reported that intermediate filaments (IFs) are pertinent in vitro PKC substrates (Inagaki et al., 1987a (Inagaki et al., , 1988 Gonda et al., 1990; Yano et al., 1991b) . During mitosis, IFs undergo dynamic change in organization accompanied with phosphorylation. It has been reported that the reorganization of cytoplasmic IFs during mitosis is mediated by phosphorylation of vimentin by cdc2 kinase (Chou et al., 1990; Matsuoka et al., 1992; Tsujimura et al., 1994) , but it has also been reported that multiple kinases are responsible for the phosphorylation of vimentin during mitosis, which may function in conjunction with cdc2 kinase in mediating IF reorganization (Evans, 1989; Chou et al., 1990) . However, only cdc2 kinase has been identified as a mitotic vimentin kinase.
To investigate the pathway of signaling between PKC and vimentin, we recently developed the monoclonal antibody YT33 which recognizes the phosphorylated state of vimentin by PKC at its specific site of phosphorylation, Ser33 (Ogawara et al., 1995) . Using antibody YT33, we found that in differentiated astrocytes, endogenous PKC activated by phosphatidylinositol 4,5-bisphosphate (PIPE) hydrolysis or a phorbol ester did not lead to phosphorylation of vimentin by PKC. Because ectopic expression of constitutively active PKC induced Ser33-phosphorylation of vimentin and reorganization of its filament networks, we considered that activated PKC is kept apart from vi-mentin during signaling in differentiated cells. However, PKC signaling to vimentin during the cell cycle remains to be investigated.
In the present study, we used the antibody YT33 and the newly developed antibody TM50 which recognize the phosphorylated states of vimentin by PKC at distinct phosphorylation sites. We report here that PKC acts as an in vivo vimentin kinase specifically during mitosis. The compartmentalization between activated PKC and vimentin filaments in mitotic cells differs from that in interphase cells. We discuss the putative mechanism in which PKC phosphorylates a cytoskeletal protein vimentin specifically during mitosis. The spatial change of activated PKC may be regulated by reorganization of intracellular membranes which supply PKC with phospholipids indispensable for activation.
Materials and Methods

Preparation of Proteins
Recombinant vimentin was prepared from E. coli as described previously (Ogawara et al., 1995) . The catalytic subunit of cAMP-dependent protein kinase (A kinase), Ca2+-calmodulin--dependent protein kinase II (CaM kinase II), PKC, and cdc2 kinase were prepared as described previously (Beavo et al., 1974; Yamauchi and Fujisawa, 1983; Inagaki et al., 1985 Inagaki et al., , 1987b Kusubata et al., 1992) . Protein concentrations were measured according to Bradford (1976) with bovine serum albumin as standard. Purified vimentin (0.15 mg/ml) was phosphorylated by incubation with 5 p,g/ ml of the catalytic subunit of A kinase, 5 Izg/ml of PKC, 0.5 i~g/ml of cdc2 kinase, or 5 I~g/ml of CaM kinase II, as described previously (Tsujimura et al., 1994) .
Peptide Synthesis
Vimentin peptides, PV6 (Cys-Ser-Thr-Arg-Ser-Val-phosphoSerr-Ser-SerSer-Tyr-Arg), PV24 (Cys-Thr-Ser-Ser-Arg-Pro-phosphoSer24-Ser-Asn-ArgSer-Tyr), PV33 (Cys-Ser-Tyr-Val-Thr-Thr-phosphoSera3-Thr-Arg-Thr-TyrSer), V33 (Cys-Ser-Tyr-Val-Thr-Thr-Sera3-Thr-Arg-Thr-Tyr-Ser), PV41 (CysThr-Tyr-Ser-Leu-Gly-phosphoSer41-Ala-Leu-Arg-Pro-Ser), PV50 (Cys-ProSer-Thr-Ser-Arg-phosphoSerS°-Leu-Tyr-Ser-Ser-Ser), V50 (Cys-Pro-Ser-ThrSer-Arg-SerS°-Leu-Tyr-Ser-Ser-Ser), PV55 (Ser-Leu-Tyr-Ala-Ser-phosphoSer55-Pro-Gly-Gly-Val-Tyr-Cys), PV65 (Cys-Tyr-Val-Thr-Arg-Ser-phosphoSer65-Ala-Val-Arg-Leu-Arg), and PV82 (Cys-Arg-Leu-Leu-Gln-AspphosphoSera2-Val-Asp-Phe-Ser-Leu) were synthesized as described previously (Tsujimura et al., 1994) .
Preparation of Mouse-Monoclonal Antibodies 4A4 and YT33
Mouse-monoclonal antibodies against PV55 (4A4) and PV33 (YT33) were prepared as described previously Tsujimura et al., 1994; Ogawara et al., 1995) .
Production of Rat-Monoclonal Antibody TM50
Phosphopeptide PV50 was conjugated to keyhole limpet hemocyanin and injected into female Jcl:Wister rats via hind footpads. The enlarged medial iliac lymph nodes from the injected rats were used for cell fusion after the method described in detail elsewhere (Kishiro et al., 1995) .
Cell Preparation
U251 human astrocytoma cells and MDBK bovine kidney cells were cultured in Dulbecco's modified Eagle's medium containing 10% FCS.
Immunofluorescence Microscopy and Western Blotting
Immunofluorescence microscopy was performed according to the previously described method (Nishizawa et al., 1991) , with slight modifications.
Cells grown on cover glasses were fixed for 10 min with 3.7% formaldehyde in PBS, permeabilized for 20 min with 0.5% Triton X-100 in PBS, and then visualized by immunofluorescence, using YT33 (3 I~g/ml) or TM50 (3 ~g/ml) in PBS, as first antibodies. All the procedures for Western blotting have been described in detail elsewhere (Nishizawa et al., 1991; Yano et al., 1991a) .
Preparation of lnterphase and Mitotic Cell Lysates for Western Blotting
Cell lysates of interphase and mitotic cells for Western blotting were prepared according to the previously described method (Tsujimura et al., 1994) with slight modifications. Just before cells reached confluence, 10 ng/ml colcemid was added to the culture media, and 12 h later the mitotic cells were collected by gently shaking the culture flasks. For the collection of interphase cells, cells were cultured to reach confluence and a small number of mitotic cells were removed by gently shaking the flasks, and then cells adhering to the bottom of the flasks were used as the interphase cells. After washing with cold PBS, cell pellets were dissolved in SDS sample buffer, which contained 0.2 mg/ml Bromophenol blue, 10% glycerol, 100 mM 2-mercaptoethanol (2-ME), 2% SDS, and 62.5 mM Tris-HC1 (pH 6.8), with brief sonication.
Preparation of the Cytosol and Membrane Fractions of U251 Cells
The cytosol and membrane fractions of U251 cells were prepared according to the previously described method (Chida et al., 1986 ) with slight modifications. Interphase and mitotic U251 ceils were prepared as described above. After incubation in the presence or absence of 200 nM 12-0-tetradecanoylphorbol-13-acetate (TPA), 2.0 x 106 cells were washed with cold PBS and suspended in buffer A consisting of 2 mM ethylene glycolbis (13-aminoethyl ether) N,N,N',N',-tetraacetic acid (EGTA), 50 p,g/ml leupeptin, 50 mM 2-ME and 25 mM Tris-HC1 (pH 7.5). The cells were then homogenized and centrifuged at 100,000 g for 30 min. The supernatant was subjected to chromatography on a DEAE-cellulose (DE-52; Whatman) column (0.6 × 1.0 cm) equilibrated with buffer A. The fraction eluted with 0.4 M NaC1 was used as the preparation of the cytosol fraction. The crude membrane fraction (100,000 g precipitate) was solubilized by treatment with buffer A containing 1.0% Triton X-100 at 4°C for 30 min and centrifuged at 100,000 g for 30 min. The supernatant was subjected to chromatography on a DEAE-cellulose column (0.6 x 1.0 cm) equilibrated with buffer A. The column was washed with 5 ml of buffer A without Triton X-100. The fraction eluted with 0.4 M NaC1 was used as the preparation of the membrane fraction.
Assay of Protein Kinase C
PKC activity was assayed by measuring incorporation of 32p from [~/-32p]ATP to histone H1 according to the previously described method (Inagaki et al., 1985) with slight modifications. Each fraction (5 izl) was incubated at 25°C for 5 min with 0.5 mg/ml histone H1 (Boehringer Mannheim Corp., Indianapolis, IN) in a reaction mixture containing, in a final volume of 25 Ixl, 10 ~M [3,-32p]ATP, 0.1 p,M calyculin A, 1 mM EGTA or 0.1 mM CaC12, 2 mM MgCI2 and 25 mM Tris-HCl (pH 7.5), in the presence or absence of 200 nM TPA and 50 p,g/ml phosphatidylserine (PS). The reaction was stopped by adding 25 p~l of cold 300 mM H3PO4 and the mixture was spotted onto a P81 phosphocellulose paper. The papers were washed successively three times for 5 min in 75 mM H3PO 4 and once briefly in ethanol, dried, and then counted in a liquid scintillation counter. Activity of PKC was defined as the difference between the 32p incorporation in the presence and absence of CaC12, TPA, and PS.
Phosphorylation of Purified Vimentin by the Cytosol and Membrane Fractions of U251 Cells
Each fraction was incubated at 25°C for 30 min with 0.15 mg/ml vimentin as an exogenous substrate in a reaction mixture containing 1.0 mM ATP, 0.1 p,M calyeulin A, 1.2 mM MgC12 and 25 mM Tris-HCl (pH 7.5), in the presence or absence of 200 nM TPA, 50 p~g/ml PS, and 0.1 mM CaCI 2. The reaction was stopped by adding equal volume of SDS sample buffer.
Phosphorylation of Endogenous Vimentin in the Whole Cell Lysates of U251 Cells
Interphase and mitotic U251 cells with or without TPA treatment were suspended and sonicated in a buffer consisting of 0.5 mM dithiothreitol, 20 mM ~-glycerophosphate, 50 }xg/ml leupeptin, 10 mM 2-ME, 2 mM PMSF and 25 mM Tris-HC1 (pH 7.5). The whole cell lysates (0.6 mg protein/ml) containing endogenous vimentin were incubated at 25°C for 30 min in a reaction mixture containing 1.0 mM ATP, 0.1 }xM calyculin A, 1.2 mM MgC12, 2 mM PMSF, and 25 mM Tris-HC1 (pH 7.5). The reactions were stopped by adding an equal volume of SDS sample buffer.
Results
Is PKC a Mitotic Vimentin Kinase?
We recently developed the monoclonal antibody YT33 against a synthetic phosphopeptide PV33 (_P_hosphorylated Vimentin Set33; Cys-Ser-Tyr-Val-Thr-Thr-phosphoSer a3-Thr-Arg-Thr-Tyr-Ser, residues 28-38 of vimentin) (Ogawara et al., 1995) . Vimentin-Ser33 has been identified as a PKC phosphorylation site in vitro (Ando et al., 1989) .
The reactivity of the antibody YT33 to nonphosphorylated vimentin and phosphorylated vimentin by various protein kinases was analyzed by Western blotting. Recombinant mouse nonphosphorylated vimentin and vimentin phosphorylated by cAMP-dependent protein kinase, PKC, cdc2 kinase, and CaE÷-calmodulin-dependent protein kinase II were resolved by SDS-PAGE, and blots were stained with the antibody YT33 (Fig. 1 A) . The antibody YT33 reacted only with vimentin phosphorylated by PKC and did not react with nonphosphorylated vimentin or vimentin phosphorylated by other protein kinases. Next, we examined the sensitivity of the antibody YT33 to phosphorylated vimentin by PKC (Fig. 1 B) . While vimentin has 11 known sites of phosphorylation for PKC (Ando et al., 1989) , the antibody YT33 showed sensitivity high enough to detect vimentin phosphorylated at 0.3 mol phosphate/ mol vimentin by PKC. We also examined the specificity of the antibody YT33 to vimentin phosphorylated at Set33 (Fig. 1 C) . It was neutralized by preincubation exclusively with a phosphopeptide PV33 but not with a peptide V33 (Cys-Ser-Tyr-Val-Thr-Thr-Sera3-Thr-Arg-Thr-Tyr-Ser) or other phosphopeptides such as PV6, PV24, PV41, PV50, and PV65 which were designed to represent vimentin phosphorylated at known PKC sites such as Ser6, Ser24, Ser41, Ser50, and Ser65, respectively.
To observe the in vivo phosphorylation of vimentinSer33 residues during the cell cycle, U251 human astrocytoma cells and MDBK bovine kidney cells were stained with the YT33 antibody. As we noted previously in primary cultured astrocytes (Ogawara et al., 1995) , U251 and MDBK cells in interphase showed no YT33 immunoreactivity. On the other hand, YT33 immunostained an intricate mesh of vimentin filament in the entire cytoplasm of mitotic cells (Fig. 2, A and B) . These results suggest that vimentin-Ser33 is phosphorylated specifically during mitosis.
To confirm the mitosis-specific phosphorylation of vimentin-Ser33, Western blots were prepared. Whole cell lysates of interphase and mitotic U251 and MDBK cells were stained with the YT33 antibody. As shown in 
Temporal Change of Vimentin-Ser33 Phosphorylation by PKC during Mitosis
We then examined the temporal change of phosphorylation-dephosphorylation of vimentin-Ser33 observed in mitotic U251 cells. Ser33-phosphorylation was started at metaphase and maintained throughout anaphase as shown in Fig. 3 A. Similar results were obtained when MDBK cells were stained (data not shown). These patterns of staining differed from those of a monoclonal antibody 4A4 which specifically recognizes cdc2 kinase-phosphorylated vimentin (Fig. 3 B; Tsujimura et al., 1994) . Thus, PKC may act as a mitotic vimentin kinase on a time schedule that differs from vimentin phosphorylation by cdc2 kinase.
Antibody Specific to Phosphorylated Vimentin at a Distinct PKC Site, Ser50
To determine whether or not PKC is a mitotic vimentin kinase, we developed another monoclonal antibody TM50 (1 p~g/ml) after absorption with synthetic peptides (50 p~g/ml of V50 (b) 
, PV50 (c), PV6 (d), PV24 (e), PV33 (f), PV41 (g) or PV65 (h)).
Lane ( a peptide V50 (Cys-Pro-Ser-Thr-Ser-Arg-SeIS°-Leu-TyrSer-Ser-Ser) or a phosphopeptide such as PV6, PV24, PV33, PV41, and PV65 (Fig. 4 A) .
In Western blotting using whole cell lysates and TM50, an immunoreactive band at the position corresponding to that of vimentin was visible in the mitotic but not in the interphase cell lysate (Fig. 4 B) . Immunofluorescence micrography using TM50 revealed that another PKC site Ser50 on vimentin was also phosphorylated, specifically during mitosis. Furthermore, temporal change of Ser50-phosphorylation during mitosis was much the same as that of Ser33-phosphorylation (Fig. 4 C) . These results strongly suggest that PKC is a mitotic vimentin kinase.
Mitosis-specific Enhancement by TPA of Vimentin Phosphorylation by PKC
To further elucidate whether the mitosis-specific Ser33-and Ser50-phosphorylation of vimentin was carried out by PKC, we asked whether or not the PKC-activator, 12-0-tetradecanoylphorbol-13-acetate (TPA) would enhance these types of vimentin phosphorylation. As shown in Fig.  5 , the mitosis-specific Ser33-phosphorylation was significantly enhanced by treatment with TPA (large arrows).
On the other hand, TPA had no effect on vimentin phosphorylation by PKC in interphase U251 cells (small arrows), findings consistent with our previous results using differentiated astrocytes (Ogawara et al., 1995) . Similar results were obtained when MDBK cells instead of U251 cells were stained and also when the antibody TM50 was used instead of YT33 (data not shown). Western blotting revealed about three times the degree of enhancement of mitosis-specific Ser33-phosphorylation by TPA treatment (Fig. 6, A and B) . Interphase cells were not stained with the antibody YT33 even when U251 cells were treated with a phosphatase inhibitor calyculin A (10 nM) alone or with calyculin A and TPA (data not shown). After 20-30 min in the presence of calyculin A, an increasing number of the cells showed a more rounded morphology as described previously (Eriksson et al., 1992) , but interphase cells were not stained with the antibody YT33 (data not shown). These results suggest that PKC can phosphorylate vimentin specifically in mitotic cells and not in interphase cells, even in case of TPA and/or phosphatase inhibitor treatment.
Subcellular Localization of PKC Activity in Interphase and Mitotic Cells
To investigate mechanism(s) involved in the mitosis-specific vimentin phosphorylation by PKC, we examined whether PKC is activated when cells enter mitosis. Because PKC is redistributed from the cytosol to the membrane fraction when activated by PIP 2 hydrolysis or phorbol esters (Kraft and Anderson, 1983) , we checked the subcellular localization of PKC activity in interphase and mitotic U251 cells. PKC activity of each subcellular fraction was assayed by measuring incorporation of phosphate into histone H1 (Fig. 7 A) . In interphase U251 cells, ~70% of the PKC activity was found in the cytosol fraction and 30% in the membrane fraction. In mitotic U251 cells, the subcellular localization of PKC activity was similar to that in interphase ceils.
Next, we wanted to determine if PKC is activated when interphase and mitotic cells are treated with TPA. By treatment with 200 nM TPA, the PKC activity in the cytosol fraction of both interphase and mitotic cells disappeared almost completely while the activity in the membrane fraction increased to the level almost equal to the total PKC activity seen in untreated cells (Fig. 7 A) . Instead of histone HI, we incubated purified vimentin as an exogenous substrate with each fraction, which was depleted of endogenous vimentin and membrane phospholipid, in the presence or absence of PKC activators such as TPA, phosphatidylserine (PS) and CaC12, and then assayed the activity for Ser33-phosphorylation of vimentin by Western blotting using the YT33 antibody. No Ser33-phosphorylation was detected when vimentin was incubated in the absence of PKC activators (Fig. 7 B; upper panel). In the presence of PKC activators, vimentin-Ser33-phosphorylation demonstrated almost the same subcellular localization of the activity as demonstrated by histone Hl-phosphorylation (Fig. 7 B; lower panel) . These results support the possibility that PKC is the only protein kinase in intcrphase and mitotic cell lysates which phosphorylates vimentin-Ser33. Subcellular localization of PKC activity assayed by measuring phosphorylation of histone H1 and vimentin-Ser33 suggests that PKC redistribution does not occur when cells enter mitosis and that PKC is redistributed and activated by TPA treatment in both interphase and mitotic cells. In other words, the mitosis-specific vimentin phosphorylation by PKC is not coupled with PKC redistribution.
Disruption of SubceUular Compartmentalization of Interphase Cells Leads to Vimentin Phosphorylation by PKC
Interphase and mitotic U251 cells with or without TPA treatment were sonicated and whole cell lysates were prepared. After the incubation of whole cell lysates in the presence of ATP, Ser33-phosphorylation of endogenous vimentin was detected in the whole cell lysates prepared from interphase cells as well as in those from mitotic cells (Fig. 8) . Moreover, a significantly higher level of Set33-phosphorylation of vimentin was observed in the sample prepared from TPA-treated interphase cells, compared to untreated interphase cells. Similar results were obtained when mitotic cells were used. These results indicate that the disruption of subcellular compartmentalization of interphase ceils leads to vimentin phosphorylation by PKC.
Discussion
In the present study, we presented evidence for the in vivo phosphorylation of vimentin by PKC specifically during mitosis, using two types of phosphorylated state-specific antibodies (Figs. 1--4) . Furthermore, we demonstrated that TPA-induced enhancement of vimentin phosphorylation by PKC is also mitosis-specific (Figs. 5 and 6 ). In addition to these observations, we tried to inhibit Set33-and Ser50-phosphorylation of vimentin during mitosis using PKC inhibitors such as H7 and calphostin C. However, it was impossible to obtain evidence for inhibition of the mitosisspecific Set33-or SerS0-phosphorylation by PKC inhibitors because they prevented cells from entering mitosis (Usui et al., 1991; Mifiana et al., 1992) .
Why vimentin phosphorylation by PKC is mitosis-specific has to be addressed. Subcellular localization of PKC in mitotic cells is similar to that in interphase cells, and TPA induces PKC redistribution from the cytosol to the membrane fraction in both interphase and mitotic cells (Fig. 7) . Since the disruption of subcellular compartmentalization of interphase cells leads to vimentin phosphorylation by PKC (Fig. 8) , we propose mechanisms for the mitosis-specific phosphorylation of vimentin by PKC outlined in Fig. 9 . In interphase cells (Fig. 9 A) , the majority of PKCs are distributed in the cytosol fraction while some PKCs are distributed in the membrane fraction. When interphase cells are treated with TPA ( Fig. 9 B) , most PKCs in the cytosol fraction are redistributed to the membrane fraction. The membrane-bound PKCs cannot encounter and phosphorylate vimentin because of structural organization of intracellular membranes such as nuclear envelopes (NE), endoplasmic reticulums (ER), and Golgi apparatus. When cells enter mitosis (Fig. 9 C) , however, structure of the intracellular membranes disassemble into . Schematic representation of the mechanism of mitosisspecific phosphorylation of vimentin filament by protein kinase C. Activated protein kinase C (AC) was assumed to be almost membrane-bound whereas inactive protein kinase C (IC) to be almost cytosolic. ER, endoplasmic reticulum; MV, membrane vesicles; NE, nuclear envelope; PM, plasma membrane; Vim, vimentin filament. P denotes the phosphorylation of vimentin filament by protein kinase C.
the form of vesicles (MV, membrane vesicles) (Zeligs and Wollman, 1979; Gerace and Blobel, 1980) . Thus, the MVbound PKCs do encounter and phosphorylate vimentin. In TPA-treated mitotic cells (Fig. 9 D) , an increased number of MV-bound PKCs encounter and phosphorylate vimentin. In other words, the mitosis-specific vimentin phosphorylation by PKC may be caused by mitosis-specific targeting of activated PKC to vimentin coupled with reorganization of intracellular membranes. It has been reported that vimentin filaments bind under in vitro conditions to vesicles reconstituted from total cellular lipids and phospholipid mixtures (Traub et al., 1986) . Vimentin is also known to form a filament basket around lipid globules present in differentiating adipocytes. The IF basket is "sandwiched" between the surface of the globule and a flat, fenestrated membrane cisterna (Franke et al., 1987) . It was also reported that vimentin filaments of mitotically arrested cells are associated with nuclear membrane vesicles and that their binding to vimentin is modulated by phosphorylation and dephosphorylation (Maison et aL, 1993) . These vimentin-membrane interactions support our proposal (Fig. 9) for mechanisms by which PKC exerts activity to phosphorylate vimentin specifically during mitosis.
Like the vimentin phosphorylation, phosphorylation of other PKC substrates may possibly be regulated by mitosis-specific targeting coupled with the reorganization of intracellular membranes. Therefore, our proposal also implies that during mitosis, PKC may phosphorylate an additional subset of substrates not phosphorylated in interphase.
Phosphorylated state-specific antibodies which recognize the phosphorylated serine/threonine residue and its flanking sequence provide a useful tool to analyze sitespecific protein phosphorylation of a target protein in vivo (Nishizawa et al., 1991; Czernik et al., 1991; Inagaki et al., 1994a,b) . Analysis of an in vivo substrate of a kinase is feasible using phosphorylated state-specific antibodies, if they are raised against unique phospho-serine/threonine residues which are specifically catalyzed by the kinase in vitro (Tsujimura et al., 1994; Ogawara et al., 1995) . In the present study, we obtained evidence for the in vivo phosphorylation of vimentin by PKC in the cell cycle, the visualization of which was made feasible by using two monoclonal antibodies which specifically recognize vimentin phosphorylated at distinct PKC sites. Such findings suggest the spatiotemporal distribution of PKC activity in the cytoplasm during mitosis coupled with reorganization of intracellular membranes, events not recognized by means of anti-PKC antibodies or cell lines overexpressing or lacking PKC.
Because vimentin is localized only in the cytoplasm, detection of PKC activity in the membrane and nucleus is difficult using these antibodies. However, as we have shown, they are powerful tools to monitor the spatiotemporal organization of PKC activity in the cytoplasm. Analysis of the functions of activated PKC in the cytoplasm during mitosis is an area for further exploration.
